Structural biology of SARS-CoV-2: open the door for novel therapies

W Yan, Y Zheng, X Zeng, B He, W Cheng - Signal Transduction and …, 2022 - nature.com
Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …

Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review

X Li, Y Song - European Journal of Medicinal Chemistry, 2023 - Elsevier
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …

[HTML][HTML] Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics

Y Gupta, OV Savytskyi, M Coban, A Venugopal… - Molecular Aspects of …, 2023 - Elsevier
With more than 5 million fatalities and close to 300 million reported cases, COVID-19 is the
first documented pandemic due to a coronavirus that continues to be a major health …

A review of the current landscape of SARS-CoV-2 main protease inhibitors: Have we hit the bullseye yet?

G Macip, P Garcia-Segura, J Mestres-Truyol… - International journal of …, 2021 - mdpi.com
In this review, we collected 1765 severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) M-pro inhibitors from the bibliography and other sources, such as the COVID …

[HTML][HTML] Allosteric binding sites of the SARS-CoV-2 main protease: potential targets for broad-spectrum anti-coronavirus agents

L Alzyoud, MA Ghattas, N Atatreh - Drug Design, Development and …, 2022 - ncbi.nlm.nih.gov
The current pandemic caused by the COVID-19 disease has reached everywhere in the
world and has affected every aspect of our lives. As of the current data, the World Health …

A strategy for evaluating potential antiviral resistance to small molecule drugs and application to SARS-CoV-2

K Sargsyan, K Mazmanian, C Lim - Scientific Reports, 2023 - nature.com
Alterations in viral fitness cannot be inferred from only mutagenesis studies of an isolated
viral protein. To-date, no systematic analysis has been performed to identify mutations that …

[HTML][HTML] An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: promises and challenges

X Xu, Y Chen, X Lu, W Zhang, W Fang, L Yuan… - Biochemical …, 2022 - Elsevier
The highly transmissible variants of SARS-CoV-2, the causative pathogen of the COVID-19
pandemic, bring new waves of infection worldwide. Identification of effective therapeutic …

Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo

H Peng, C Ding, L Jiang, W Tang, Y Liu, L Zhao… - Science China Life …, 2022 - Springer
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global crisis. Clinical candidates with …

Discovery of All-d-Peptide Inhibitors of SARS-CoV-2 3C-like Protease

RJ Eberle, M Sevenich, I Gering, L Scharbert… - ACS chemical …, 2023 - ACS Publications
During the replication process of SARS-CoV-2, the main protease of the virus [3-
chymotrypsin-like protease (3CLpro)] plays a pivotal role and is essential for the life cycle of …

[HTML][HTML] Suramin inhibits SARS-CoV-2 nucleocapsid phosphoprotein genome packaging function

I Boniardi, A Corona, J Basquin, C Basquin, J Milia… - Virus Research, 2023 - Elsevier
Abstract The coronavirus disease 2019 (COVID-19) pandemic is fading, however its
etiologic agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues …